| Supplier: | Boster |
|---|---|
| Reference: | M00010 |
| Name: | Anti-HER-2 / c-erbB-2 / neu / CD340 Monoclonal Antibody |
| Category: | Antibody |
| Subcategory: | Primary Antibodies,Monoclonal Antibodies |
| Research Area: | Cancer,Cell Type Markers,Growth Factors,Growth Factors/Hormones,Oncoproteins,Protein Phosphorylation,Receptor Tyrosine Kinases,Signal Transduction,Tags & Cell Markers,Tumor Associated,Tumor Biomarkers,Tumor Immunology,Tumor-Associated Antigens,Tyrosine Ki |
| Aditional Names: | Receptor tyrosine-protein kinase erbB-2;2.7.10.1;Metastatic lymph node gene 19 protein;MLN 19;Proto-oncogene Neu;Proto-oncogene c-ErbB-2;Tyrosine kinase-type cell surface receptor HER2;p185erbB2;CD340;ERBB2;HER2, MLN19, NEU, NGL; |
| Unit: | 100ug |
| Concentration: | Purified antibody with BSA and azide at 200ug/ml |
| Clonality: | Monoclonal |
| Price: | Consultar |
| Format: | Liquid |
| Immunogen: | Recombinant intracellular domain of human HER-2 prot |
| Host: | Mouse |
| Reactivity: | Human |
| Application: | ELISA,Flow Cytometry,IF |
| Description: | Boster Bio Anti-HER-2 / c-erbB-2 / neu / CD340 Monoclonal Antibody (Catalog # M00010). Tested in ELISA, Flow Cytometry, IF applications. This antibody reacts with Human. |
| Function: | Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a |
| Cell localization: | Cell Surface |
| Clone: | Clone: ERB2/776 |
| Isotype: | IgG1, kappa |
| Purification: | 200ug/ml of antibody purified from Bioreactor Concentrate by Protein A/G. |
| Storage conditions: | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required. |
| Assay inforation: | ELISA (For coating, order antibody without BSA) Flow Cytometry (1-2ug/million cells) Immunofluorescence (1-2ug/ml) Optimal dilution for a specific application should be determined. |